Tumor Lysis Syndrome and Primary Hepatic Malignancy: Case Presentation and Review of the Literature

Abstract

Tumor lysis syndrome (TLS) represents a constellation of laboratory and clinical derangements that can occur following treatment of malignancies with high cellular turnover. Most commonly noted in hematologic malignancies, TLS has been reported to occur following liver-directed therapy in the form of both ablative therapies and transarterial therapies. Classification schemes exist, as do established diagnostic criteria, to aid in the definitive diagnosis of TLS. In addition, treatment algorithms are reported for patients with the diagnosis of TLS. This manuscript will review the risk factors associated with the development of TLS, the diagnostic criteria used, and treatment and preventative strategies employed. In addition, an algorithm for the diagnosis and treatment of TLS will be provided.

Keywords

interventional radiology - tumor lysis syndrome - complications - chemoembolization

• References

• 1 Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008; 93 (1) 9-13
• 2 Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116 (8) 546-554
• 3 Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010; 36 (2) 164-176
• 4 Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol 2005; 3 (1) 54-61
• 5 Lehner SG, Gould JE, Saad WE, Brown DB. Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 185 (5) 1307-1309
• 6 Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6 (2) 5389
• 7 McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol 2012; 5 (75) 75
• 8 Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364 (19) 1844-1854
• 9 Hsieh P-M, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol 2009; 15 (37) 4726-4728
• 10 Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. CMAJ 2010; 182 (15) 1631-1635
• 11 Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 2010; 55 (5) (Suppl. 03) S1-S13 , quiz S14–S19
• 12 El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Acute kidney injury associated with tumor lysis syndrome: a paradigm shift. Am J Emerg Med 2012; 30 (2) 390.e3-390.e6
• 13 Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94 (2) 133-139
• 14 Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127 (1) 3-11
• 15 Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 2012; 7 (10) 1730-1739
• 16 Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 2011; 154 (1) 3-13
• 17 Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26 (16) 2767-2778
• 18 Cairo MS, Coiffier B, Reiter A, Younes A ; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149 (4) 578-586
• 19 Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006; 3 (8) 438-447
• 20 Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31 (1) 27-28
• 21 Sood AR, Burry LD, Cheng DK. Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy 2007; 27 (1) 111-121
• 22 Jeha S, Kantarjian H, Irwin D , et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19 (1) 34-38
• 23 Burney IA. Acute tumor lysis syndrome after transcatheter chemoembolization of hepatocellular carcinoma. South Med J 1998; 91 (5) 467-470
• 24 Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?. Am J Med Sci 2003; 325 (1) 38-40
• 25 Lee CC, Wu YH, Chung SH, Chen WJ. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist 2006; 11 (1) 87-88 , author reply 89
• 26 Sakamoto N, Monzawa S, Nagano H, Nishizaki H, Arai Y, Sugimura K. Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma. Cardiovasc Intervent Radiol 2007; 30 (3) 508-511
• 27 Shiba H, Ishida Y, Wakiyama S, Sakamoto T, Misawa T, Yanaga K. Acute tumor lysis syndrome after transarterial chemoembolization for hepatocellular carcinoma. Cancer Sci 2008; 99 (10) 2104-2105
• 28 Huang W-S, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 2009; 15 (35) 4464-4466
• 29 Shiozawa K, Watanabe M, Takenaka H , et al. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology 2010; 57 (101) 688-690
• 30 Chao CT, Chiang CK. Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report. Medical principles and practice: international journal of the Kuwait University. Health Science Centre 2012; 21 (5) 498-500E
• 31 Nishida Y, Fujii H, Hagihara A , et al. [Tumor lysis syndrome after transarterial embolization for hepatocellular carcinoma]. Nippon Shokakibyo Gakkai Zasshi 2013; 110 (3) 441-448
• 32 Ali AM, Barbaryan A, Zdunek T, Khan M, Voore P, Mirrakhimov AE. Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma. J Gastrointest Oncol 2014; 5 (2) E46-E49
• 33 Kekre N, Djordjevic B, Touchie C. Spontaneous tumour lysis syndrome. CMAJ 2012; 184 (8) 913-916
• 34 Wang K, Chen Z. Acute tumor lysis syndrome after transarterial chemoembolization for well-differentiated hepatocellular carcinoma with neuroendocrine features. Onkologie 2010; 33 (10) 532-535
• 35 Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004; 24 (3) 210-215